Results 141 to 150 of about 150,778 (261)

Characterisation of tumor-infiltrating gamma-delta T cells in human colorectal cancer with MHC-I loss. [PDF]

Clin Transl Immunology
Li TA, Quigley LT, Chan KF, Williams DS, Mielke LA, Behren A, Da Gama Duarte J.   +6 more
europepmc   +1 more source

Integrative Modeling in the Age of Machine Learning: A Summary of HADDOCK Strategies in CAPRI Rounds 47–55

Proteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT The HADDOCK team participated in CAPRI rounds 47–55 as server, manual predictor, and scorers. Throughout these CAPRI rounds, we used a plethora of computational strategies to predict the structure of protein complexes. Of the 10 targets comprising 24 interfaces, we achieved acceptable or better models for 3 targets in the human category and 1 ...
Victor Reys, Marco Giulini, Vlad Cojocaru, Anna Engel, Xiaotong Xu, Jorge Roel‐Touris, Cunliang Geng, Francesco Ambrosetti, Brian Jiménez‐García, Zuzana Jandova, Panagiotis I. Koukos, Charlotte van Noort, João M. C. Teixeira, Siri C. van Keulen, Manon Réau, Rodrigo V. Honorato, Alexandre M. J. J. Bonvin   +16 more
wiley   +1 more source

Major Histocompatibility Complex Class I Matching is Necessary but not Sufficient for Tolerance Induction to Vascularized Composite Allografts After Donor Hematopoietic Cell Transplantation. [PDF]

Transplant Direct
Manell E, Gunes ME, Merl S, Patwardhan S, Chauhan I, Hong J, Chen B, Jordache P, Almesalmy A, Ekanayake-Alper D, Hajosi D, Husain S, Wuu CS, Wright M, Bogue J, Rohde C, Shanmugarajah K, Cetrulo CL, Sachs DH, Weiner J.   +19 more
europepmc   +1 more source

Massive Sampling Strategy for Antibody–Antigen Targets in CAPRI Round 55 With MassiveFold

Proteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT Massive sampling with AlphaFold2 improves protein–protein complex predictions. This has been shown during the last CASP15‐CAPRI blind prediction round by the AFsample tool. However, more difficult targets including antibody–antigen binding remain challenging. CAPRI Round 55 consisted of three antibody–antigen targets and one heterotrimer.
Nessim Raouraoua, Marc F. Lensink, Guillaume Brysbaert   +2 more
wiley   +1 more source

Allele-specific KRAS signaling: shaping tumor immunity and therapeutic response in lung adenocarcinoma. [PDF]

Signal Transduct Target Ther
Papavassiliou KA, Stravopodis DJ, Papavassiliou AG.   +2 more
europepmc   +1 more source

Maintenance of histocompatibility polymorphisms [PDF]

Heredity, 1968
openaire   +2 more sources

Biomolecular Interaction Prediction in the Pre‐ and Post‐AlphaFold Era: The 8th CAPRI Evaluation

Proteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT We report on the 8th CAPRI Evaluation period, capturing the assessment of CAPRI Rounds 47 to 55 (excluding the CASP and COVID‐related Rounds), which have witnessed the transition to AI‐driven prediction tools such as AlphaFold and related alternatives. The prediction Rounds in this evaluation are characterized by a high level of difficulty due
Marc F. Lensink, Nessim Raouraoua, Guillaume Brysbaert, Sameer Velankar, Shoshana J. Wodak, Alexandre M. J. J. Bonvin   +5 more
wiley   +1 more source

Clustering-based identification of immune-related gene signatures in hepatocellular carcinoma. [PDF]

Ecancermedicalscience
Brahmaiah J, Adiga U, Augustine AJ, Vasishta S.   +3 more
europepmc   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond. [PDF]

J Immunother Precis Oncol
Low SK, Fujiwara Y, Nishizaki D, Kato S, Kurzrock R.   +4 more
europepmc   +1 more source